The audience will learn about the importance of multidisciplinary breast centres and their effect on improved detection and treatment of breast cancer. We look forward to welcome you all to get an updated information that could directly be utilised in your clinical services. Breast cancer is the leading cause of cancer death among women worldwide. Imaging plays a key role in the early detection of breast cancer. Mammography is an accepted screening modality. It has been shown that additional imaging modalities like ultrasound and MR imaging of the breast can significantly improve cancer detection and characterisation. An international classification system (BIRADS®) has been introduced and offers a global language for breast imager. In case of BIRADS® 4 and 5 lesions imaging guided biopsies are recommended before definitive surgery. The interpretation of imaging findings and pathologic results (b-classification) is essential and should be performed in multidisciplinary team conferences. It has been shown that such conferences have a strong impact on overall survival because mismanagement and failures can be reduced significantly. During this session the assembly will learn basics as well as about the importance of guidelines and risk management (failure conferences), illustrated by case studies. Clinical management of patients with HCC is a decision-making process that should be approached following evidence-based data. Staging is a relevant topic in these patients because it determines the therapeutic approach. Tumoural extension based on MRI or CT findings and prognosis assessment are critical steps in the management of patients with HCC to indicate treatment, to predict response to treatment and to predict survival. For optimal results any proposal has to take into account liver function, tumour stage and physical status. Up to now, the only proposal linking staging to prognostic prediction and treatment indication is the BCLC approach. Updated BCLC staging in 2012, first presented in 1999 in Seminars in Liver disease will be discussed and also the recent imaging features supporting the tumoural extension. Genomic studies attempted to provide the basis to identify the abnormalities that reflect a higher risk of cancer and the biological profile will be discussed. In cirrhotic liver disease those unfit for surgery but with paucinodular (usually less than 3 nodules of < 3 cm) or intermediate disease (more advanced) are increasingly amenable to locoregional therapies. Treatment in situ is, however, difficult to assess for the purposes of treatment response and continued surveillance. Modified RECIST criteria have been proposed more recently and these aim to quantify and validate in situ tumour necrosis in the late arterial phase as a valid surrogate endpoint, increasingly justified by clear survival benefit after ablation, TACE and anti-angiogenic drugs. Optimised late arterial phase imaging is critical in the diligent assessment of treatment effect and to ensure that residual disease is not left untreated. There are, however, still typical patterns of residual and recurrent disease that the radiologist must recognise whilst becoming familiar with benign post-treatment features seen after ablation and radioembolisation, for example. These can include marginal hyperaemia, portal tract oedema, arterioportal shunting, etc. Post-treatment assessment can be complex but recent work suggests that diffusion-weighted MR and increased, mapped ADC values may be useful in confirming treatment response. Careful subtraction MR (late arterial phase -baseline) has also been shown to be a robust guide to residual disease. PET/CT assessment has proved problematic due to the highly variable degree of FDG-avidity in HCC. Changes in perfusion CT parameters have been observed in different treatment response groups. With regard to ablation semi-automatic volume segmentation processing is now permitting much more accurate assessment of treatment adequacy. Medicolegal consequence is now recognised to be a major aspect of modern radiological practice. Sins of omission and commission are the building bricks of proper imaging technique in a multimodality perspective. Cirrhosis is a fertile soil for the development of different focal liver lesions, and vascular abnormalities can be now currently recognised by morphological and functional imaging including the use of cell-specific MR contrast agents. Presently, imaging acts as the common denominator in clinical decision-making, being instrumental in confirming the presence and staging of HCC and heavily influencing patient management. Apart from its diagnostic capabilities, radiology has special responsibilities in providing minimally invasive treatment options and in assessing tumour response. The current session aims to provide an overall integrated approach of the modern role of radiology in this clinical scenario, especially for all of those involved in providing consultation in a multidisciplinary environment. Although some authors still consider that fine-needle biopsy is safe, accurate, enables final diagnosis of focal liver lesions and is essential for deciding the therapeutic strategy, recent cohort studies have raised suspicions of its utility. The diagnosis with fine-needle biopsy has several limitations: location and size of tumour, clotting disorders or ascites interfere with needle insertion. False-negative results caused by sampling error may occur at a higher rate. Moreover, needle biopsy of HCC may carry a 2% to 5% risk of seeding tumour cells. Typical HCC is supplied mainly via the hepatic artery and the portal flow is lacking or reduced within the tumour. The characteristic HCC profile, including intense enhancement in AP (wash-in) and followed by contrast washout in PVP or EP (washout) on CEUS, MDCT and dynamic MR images using ordinary extracellular agents, has been established. A prospective study indicated a high PPV (> 95%) using these noninvasive imaging criteria (wash-in and washout) for diagnosis of HCC (> 1 cm), which was comparable with that of a liver biopsy. Identification of washout finding in PVP or EP is also crucial for reliable diagnosis of HCC, in particular differentiation between non-neoplastic early arterial enhancement (A-P shunt) and HCC. Based on these recent results, AASLD and EASL recommended that the diagnosis of HCC in cirrhotic patients can be made if these noninvasive imaging criteria are identified on contrast-enhanced US, MDCT or MR imaging without the use of liver biopsy. Cirrhosis is a chronic liver disease defined by the presence of fibrosis and regenerative nodules. These regenerative nodules may either remain stable or enlarge, or evolve to dysplastic nodules and hepatocellular carcinoma (HCC). This multistep carcinogenesis explains why the diagnosis of small HCC remains challenging. Other lesions such as perfusion disorders and confluent fibrosis are also often observed in cirrhosis. Last, the prevalence of peripheral cholangiocarcinoma has been shown higher than in normal livers. Therefore the goal of imaging is to provide clues which enable lesion characterisation. The classical imaging findings are mostly based on lesion size and lesion enhancement on arterial-dominant, portal venous and delayed phases. Yet, both HCCs and other lesions may show atypical enhancement. This lecture will detail the input of functional tools. For instance, combination of classical sequences and diffusion-weighted MR imaging increases distinction between HCC and other lesions developed on cirrhosis. The role and limitations of hepatospecific MR contrast agents will also be stressed.